Individual Assessment of Arteriosclerosis by Empiric Clinical Profiling
Open Access
- 28 November 2007
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 2 (11) , e1215
Abstract
Arteriosclerosis is a common cause of chronic morbidity and mortality. Myocardial infarction, stroke or other cardiovascular events identify vulnerable patients who suffer from symptomatic arteriosclerosis. Biomarkers to identify vulnerable patients before cardiovascular events occur are warranted to improve care for affected individuals. We tested how accurately basic clinical data can describe and assess the activity of arteriosclerosis in the individual patient. 269 in-patients who were treated for various conditions at the department of general medicine of an academic tertiary care center were included in a cross-sectional study. Personal history and clinical examination were obtained. When paraclinical tests were performed, the results were added to the dataset. The numerical variables in the clinical examination were statistically compared between patients with proven symptomatic arteriosclerosis (n = 100) and patients who had never experienced cardiovascular events in the past (n = 110). 25 variables were different between these two patient groups and contributed to the disease activity score. The percentile distribution of these variables defined the empiric clinical profile. Anthropometric data, signs of arterial, cardiac and renal disease, systemic inflammation and health economics formed the major categories of the empiric clinical profile that described an individual patient's disease activity. The area under the curve of the receiver operating curve for symptomatic arteriosclerosis was 0.891 (95% CI 0.799-0.983) for the novel disease activity score compared to 0.684 (95% CI 0.600-0.769) for the 10-year risk calculated according to the Framingham score. In patients suffering from symptomatic arteriosclerosis, the disease activity score deteriorated more rapidly after two years of follow-up (from 1.25 to 1.48, P = 0.005) compared to age- and sex-matched individuals free of cardiovascular events (from 1.09 to 1.19, P = 0.125). Empiric clinical profiling and the disease activity score that are based on accessible, available and affordable clinical data are valid markers for symptomatic arteriosclerosis.Keywords
This publication has 37 references indexed in Scilit:
- Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and FuturePharmacological Reviews, 2007
- From Vulnerable Plaque to Vulnerable Patient—Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force ReportThe American Journal of Cardiology, 2006
- The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study designAmerican Heart Journal, 2006
- Prevalence of Echocardiographic Left Ventricular Hypertrophy in Persons With Systemic Hypertension, Coronary Artery Disease, and Peripheral Arterial Disease and in Persons With Systemic Hypertension, Coronary Artery Disease, and No Peripheral Arterial DiseaseThe American Journal of Cardiology, 2005
- Swiss Atherothrombosis Survey: a field report on the occurrence of symptomatic and asymptomatic peripheral arterial diseaseJournal of Internal Medicine, 2005
- Kidney in Early AtherosclerosisHypertension, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- From Vulnerable Plaque to Vulnerable PatientCirculation, 2003
- A Genomic-Systems Biology Map for Cardiovascular FunctionScience, 2001
- Upper body adiposity and the risk for atherosclerosis.Journal of the American College of Nutrition, 1989